10 March

Barcoded Nanoparticles for Precision Cancer Medicine: Effects of tumor type and patient sex on anticancer efficacy

Thursday 10 March 2022, 03:00pm

ONLINE Event Via Zoom

Jointly organised by Nanomedicine Lab, Manchester University and ICN2.

ONLINE EVENT -  Register HERE to attend (14:00 (UK) / 15:00 (CET) 

Nanoseminar in Medicine & Health by: Prof. Avi Schroeder, Technion – Israel Institute of Technology, Haifa

Abstract: Medicine is taking its first steps towards patient-specific cancer care. Nanoparticles have many potential benefits for treating cancer, including the ability to transport complex molecular cargoes including siRNA and protein, as well as targeting to specific cell populations.

The talk will discuss ‘barcoded nanoparticles’ that target sites of cancer where they perform a programmed therapeutic task. Specifically, liposomes that diagnose the tumor and metastasis for their sensitivity to different medications, providing patient-specific drug activity information that can be used to improve the medication choice.

The talk will also describe how liposomes can be used for degrading the pancreatic stroma to allow subsequent drug penetration into pancreatic adenocarcinoma, and how nanoparticle’ biodistribution and anti-cancer efficacy is impacted by patient’ sex and more specifically, the menstrual cycle.

The evolution of drug delivery systems into synthetic cells, programmed nanoparticles that have an autonomous capacity to synthesize diagnostic and therapeutic proteins inside the body, and their promise for treating cancer and immunotherapy, will be discussed

Introductory talk: "Targeting the tumor-microenvironment using nanotechnology" by Dr Hanan Abumanhal-Masarweh, Associate Researcher, Division of Pharmacy & Optometry, University of Manchester